Form 8-K - Current report:
SEC Accession No. 0001558370-25-003344
Filing Date
2025-03-20
Accepted
2025-03-20 07:31:11
Documents
16
Period of Report
2025-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mtva-20250320x8k.htm   iXBRL 8-K 45005
2 EX-99.1 mtva-20250320xex99d1.htm EX-99.1 149492
3 GRAPHIC mtva-20250320x8k001.jpg GRAPHIC 9107
4 GRAPHIC mtva-20250320xex99d1001.jpg GRAPHIC 16884
  Complete submission text file 0001558370-25-003344.txt   377063

Data Files

Seq Description Document Type Size
5 EX-101.SCH mtva-20250320.xsd EX-101.SCH 3413
6 EX-101.LAB mtva-20250320_lab.xml EX-101.LAB 15929
7 EX-101.PRE mtva-20250320_pre.xml EX-101.PRE 10056
18 EXTRACTED XBRL INSTANCE DOCUMENT mtva-20250320x8k_htm.xml XML 4854
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
MetaVia Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 25754507
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)